丙型肝炎患者血清抗丙型肝炎病毒性抗IgM及HCVRN…

用酶联免疫吸附试验对住院病人抗丙型肝炎病毒抗体阳性血清标本进行抗－ＨＣＶＩｇＭ的检测，并与ＨＣＶＲＮＡ检测结果比较。结果表明，ＨＣＶＲＮＡ阳性、抗－ＨＣＶ阳性，ＨＣＶＲＮＡ阳性，抗－ＨＣＶ阴性及ＨＣＶＲＮＡ阴性，抗－ＨＣＶ阳性三类型中均有抗－ＨＣＶＩｇＭ阳性者。     

用ELISA捕获法测抗甲型肝炎病毒IgG及与竞争法测抗甲型肝炎病毒的比较

用抗甲型肝炎病毒（ＨＡＶ）ＩｇＧ阴性血清处理以抑制非特异反应，提高灵敏性的捕获法酶联免疫吸附试验检测甲型肝炎病毒特异ＩｇＧ抗体，并与竞争法检测总抗ＨＡＶ进行了比较。结果为甲型肝炎患者发病早期血清１：２０稀释时，抗ＨＡＶＩｇＧ２８／３０例阳性，总抗ＨＡＶ３０／３０例阳性。血清１：１０００稀释时，则抗ＨＡＶＩｇＧ为８／３０例阳性，总抗ＨＡＶ２９／３０例阳性。若以此稀释度为诊断界限，８例抗ＨＡＶＩｇＧ阳性出现于发病第１０至１４天。实验提示甲型肝炎患者发病早期已产生抗ＨＡＶＩｇＧ，而仅测总抗ＨＡＶ是不能区别抗体类型的。     

丙型肝炎患者血清抗丙型肝炎病毒抗体IgM及HCVRNA检测结果的比较

用酶联免疫吸附试验（ＥＬＩＳＡ）对住院病人抗丙型肝炎病毒抗体（抗－ＨＣＶ）阳性血清标本进行抗－ＨＣＶＩｇＭ的检测，并与ＨＣＶＲＮＡ检测结果比较。结果表明，ＨＣＶＲＮＡ阳性、抗－ＨＣＶ阳性，ＨＣＶＲＮＡ阳性、抗－ＨＣＶ阴性及ＨＣＶＲＮＡ阴性、抗－ＨＣＶ阳性三种类型中均有抗－ＨＣＶＩｇＭ阳性者。结果还表明ＨＣＶＲＮＡ阳性病例的抗－ＨＣＶＩｇＭ阳性率明显高于ＨＣＶＲＮＡ阴性的病例（Ｐ＜０．０５），在临床诊断上ＨＣＶＲＮＡ阳性与阴性病例的肝病大多数为急性肝炎（ＡＨ）和慢性活动性肝炎（ＣＡＨ），ＨＣＶＲＮＡ阳性与阴性比较，各类肝病的病例数无明显差别。     

散发性急性戊型肝炎血清抗体动态变化和肝脏超微结构的病理观察

为探讨散发性戊型肝炎血清抗体动态变化，应用酶联免疫法（ＥＩＡ）检测了７例急性戊型肝炎患者抗戊型肝炎病毒（ＨＥＶ）ＩｇＧ和ＩｇＭ抗体，并对１例患者进行了肝超微结构病理检测。结果表明，发病后１０天至４５天内抗ＨＥＶ－ＩｇＧ和ＩｇＭ滴度最高，发病第４０天仍有肝细胞肿胀，胞浆空化和线粒体固缩等病理变化。患者血清抗－ＨＥＶＩｇＭ滴度在４５天后逐渐下降，２个月内全部消失，抗－ＨＥＶＩｇＧ消长情况与ＩｇＭ相似，但在７个月时仍有３例（４３％）抗体阳性。     

甲型肝炎病毒免疫接种后人群特异性IgG抗体水平的动态观察

甲型肝炎病毒免疫接种后人群特异性ＩｇＧ抗体水平的动态观察王昆英黄萍（武汉市武昌区卫生防疫站，武汉４３００７１）ＨＡＶ减毒活疫苗的接种，是预防甲型肝炎流行，降低感染率的有效手段，而ＨＡＶ易感率的高低是由人群中ＨＡＶ特异性ＩｇＧ抗体水平来决定的。本文动态...     

散发性急性戊型肝炎血清抗体动态变化和肝脏超微…

为探讨散发性戊型肝为血清抗体动态变化，应用酶联免疫法（ＥＩＡ）检测了７例急性戊型肝炎抗戊型肝炎病毒（ＨＥＶ）ＩｇＧ和ＩｇＭ抗体、并对１例２进行了肝超微结构病理检测，结果表明，发病１０天至４５天内抗ＨＥＶ－ＩｇＧ和ＩｇＭ滴度最高，发病第４０天仍有肝细胞肿胀，胞浆空化和线粒体固缩等病理变化。患者轿清抗－ＨＥＶＩｇＭ滴度在４５天后逐渐下降，２个月内全中消失，抗－ＨＥＶＩｇＭ滴度在４５天后逐渐下降，２个月     

1984-1995年12年间西安地区孕妇TORCH特异性抗体检测结果分析

本文报告自１９８４年１月至１９９５年５月间西安地区孕妇ＴＯＲＣＨ特异性抗体检测结果分析。本室用微量间接血凝法及ＥＬＩＳＡ法对孕妇血清分别检测弓形体抗体（ＴＰ－Ａｂ）３１４４例、抗风疹病毒ＩｇＭ（ＲＶ－ＩｇＭ）９２０例、抗巨细胞病毒ＩｇＭ（ＣＭＶ－ＩｇＭ）１４５４例、抗单纯疱疹病毒Ⅱ型ＩｇＭ（ＨＳＶⅡ－ＩｇＭ）９５９例，其结果阳性率分别为３．６６％０．１１％、１１．２８％、３．０２％。其中，早孕和中晚孕孕妇间的各项特异性抗体阳性率均无显著性差异（Ｐ＞０．０５）；有无上感病史孕妇间的ＴＰ－Ａｂ、ＣＭＶ－ＩｇＭ、ＨＳＶⅡ－ＩｇＭ阳性率均无显著性差异（Ｐ＞０．０５）；不同职业孕妇的ＴＰ－Ａｂ阳性率亦无显著性差异（Ｐ＞０．０５）。从而得知，对所有的孕妇在孕期进行ＴＯＲＣＨ感染检测，对于作好优生工作有重要的意义。     

831名健康青年庚型肝炎病毒和人免疫缺陷病毒感染？…

目的 了解我国健康青年中庚型肝炎病毒（ＨＧＶ）和人免疫缺陷病毒的感染情况。方法 采用酶联免疫法（ＥＩＡ）检测６省８３１名健康青年血清中的ＨＧＶ和ＨＩＶ抗体，对抗－ＨＧＶＩｇＧ阳性的血清再用逆转录－巢式聚合酶链反应（ＲＴ－ＰＣＲ）检测ＨＧＶＲＮＡ。结果 发现抗－ＨＧＶ ＩｇＧ阳性率为２．５３％（２１／８３１），２１例阳性者中ＨＧＶ ＲＮＡ阳性８例，两者符合率为３８．１％；抗－ＨＩＶ均阴性。结论 我     

不同人群庚型肝炎病毒感染状况分析

为了解不同人群庚型肝炎病毒（ＨＧＶ）感染状况，采用优化的ＨＧＶＮＳ５区两条合成肽为抗原，建立间接酶联免疫吸附试验（ＥＬＩＳＡ），检测了１２０９例不同人群血清中抗－ＨＧＶＩｇＧ，总阳性率为３．８％，其中非Ａ～Ｅ型肝炎患者抗－ＨＧＶＩｇＧ阳性率最高，为２０．５％，明显高于自然人群的０．８％和其它肝炎患者（Ａ～Ｅ型）的３．３％，丙型肝炎患者中抗－ＨＧＶＩｇＧ阳性率亦较高，为８．０％。职业献血员抗－ＨＧＶＩｇＧ阳性率３．４％高于义务献血员０．０％。性病患者阳性率为３．６％，有静脉吸毒史的ＨＩＶ感染者阳性率亦较高，为８．０％。结果表明，ＨＧＶ在我国有较高的感染率；ＨＧＶ可能为非Ａ～Ｅ型肝炎的重要致病因子；职业献血员和有血液接触史者ＨＧＶ感染率较高，提示血源应严格筛选     

用重组结构区抗原检测抗丙型肝炎病毒IgM抗体方法的建立

目的检测抗丙型肝炎病毒（ＨＣＶ）结构区蛋白ＩｇＭ抗体。方法采用丙型肝炎病毒Ｃ，Ｅ１，Ｅ２区重组抗原混合包被和分别包被酶标板；用兔抗人γ链血清处理人血清标本，再用固相包被羊抗兔抗体吸附兔抗人γ链－人ＩｇＧ复合物，建立了抗－ＨＣＶＩｇＭ检测方法。结果对７６例丙型肝炎病人血清进行抗－ＨＣＶＩｇＭ检测，同时与逆转录－巢式聚合酶链反应（ＲＴ－ＰＣＲ）检测结果进行比较，两者具有相关性（Ｐ＜０００５）；ＩｇＭ抗体组成分析结果表明采用全片段Ｃ、Ｃ＋Ｅ２区抗原血清标本中的抗－ＨＣＶＩｇＭ检出率分别可达９６６％和１００％。结论ＨＣＶ的Ｃ、Ｅ２重组抗原用于抗－ＨＣＶＩｇＭ检测具有较高的敏感度和特异性。     

Viral excretion and antibody titers in children infected with hepatitis A virus from an orphanage in western India

BackgroundHepatitis A is endemic in India and mainly causes sporadic infections. However, children in childcare centers, schools and orphanages are vulnerable to common-source outbreaks as they have naive hosts.ObjectivesTo investigate hepatitis A outbreak in an orphanage from Pune, India.Study DesignMonitoring of virus excretion and anti-HAV antibody levels in hepatitis A virus (HAV) infected children.ResultsThe orphanage housed 93 children of the age 1 month-6.5 years. Analysis of the collected serum (n = 78) and stool samples (n = 63) revealed 20 children to be either positive for anti-HAV IgM antibodies or excreting HAV, 14 being symptomatic and 6 asymptomatic, while 32 were already anti-HAV IgG positive either due to past HAV exposure (n = 7, mean log antibody titers: 2.96) or maternal antibodies (n = 25, mean log antibody titers: 1.13). Serum samples, taken 4 weeks apart, did not show any significant difference in the IgM and IgG antibody levels either. However, virus excretion decreased significantly after 15 days in symptomatic children (mean log HAV RNA copies/ml 1.03 + 0.30), while asymptomatic children continued to excrete higher viral loads, at constant levels (mean log HAV RNA copies/ml 2.33 + 0.33), for up to 90 days.ConclusionsThough virus excretion continued up to 90 days in all HAV infected children, asymptomatic children excreted higher viral loads for longer period and hence can contribute significantly in person-to-person virus transmission. All children should be vaccinated in such set ups.     

Optimal time for repeating the IgM anti-hepatitis A virus antibody test in acute hepatitis A patients with a negative initial test

Background/Aims

The nonspecific clinical presentation of acute hepatitis A (AHA) mandates the detection of anti-hepatitis A virus IgM antibodies (IgM anti-HAV) in the serum for obtaining a definitive diagnosis. However, IgM anti-HAV might not be present during the early phase of the disease. The aim of this study was to determine the optimal time for repeating the IgM anti-HAV test (HAV test) in AHA patients with a negative initial test.

Methods

In total, 261 patients hospitalized with AHA were enrolled for this retrospective study. AHA was diagnosed when the test for IgM anti-HAV was positive and the serum alanine aminotransferase (ALT) level was ≥400 IU/L. Repeat HAV test was conducted after 1-2 weeks if the initial HAV test was negative but AHA was still clinically suspected.

Results

The results of the initial HAV test were negative in 28 (10.7%) patients. The intervals from symptom onset to the initial-HAV-test day and from the peak-ALT day to the initial-HAV-test day were significantly shorter in the negative-initial-HAV-test group, but on multivariate analysis only the latter was significantly associated with negative results for the initial HAV test (β=-0.978; odds ratio [95% confidence interval]=0.376 [0.189-0.747]; P=0.005). The HAV test was positive in all patients when it was performed at least 2 days after the peak-ALT day.

Conclusions

The results of HAV tests were significantly associated with the interval from the peak-ALT day to the HAV-test day. The optimal time for repeating the HAV test in clinically suspicious AHA patients with a negative initial HAV test appears to be at least 2 days after the peak-ALT day.     

Current seroepidemiology of hepatitis A in Hong Kong.

The current seroepidemiology of hepatitis A in Hong Kong was examined by testing stored sera from 702 healthy subjects, collected between 1987-1989, for antibody to hepatitis A virus (anti-HAV). The overall prevalence of anti-HAV antibody was 45.6%. There were significant increases in prevalence of anti-HAV antibody with every 10-year increase in age up to age 40. The prevalence of anti-HAV antibody was 24% for subjects below age 30 and 89.2% for those above age 30 (P less than 0.0001). Socioeconomic factors did not appear to have any influence on the prevalence of anti-HAV antibody. In comparison with another study conducted in Hong Kong 10 years ago, the prevalence of anti-HAV antibody in the current study was significantly lower in every age group from 0 to 30 years. In summary, it was shown that HAV infection is no longer highly endemic in Hong Kong. In view of the changing epidemiology, postexposure prophylaxis will be necessary for young adults and children, and hepatitis A vaccine may be indicated for high risk groups when it is generally available.     

Detection and persistence of specific IgA antibodies in serum of patients with hepatitis A by capture radioimmunoassay

The serum immunoglobulin A (IgA) response to hepatitis A virus (HAV) was investigated with a sensitive capture radioimmunoassay. In serial serum samples drawn from 15 patients with viral hepatitis A, IgA anti-HAV antibodies reached their highest titer between 1-2 weeks after onset and peak titers ranged from 10,000-20,000. Serum samples were available from six patients 30-32 months after onset of illness. These samples were all positive for IgA anti-HAV and some had titers similar to peak titers during illness. However, the height of the titration curves, expressed as the binding ratio (BR) at a dilution of 1/1000, was in all cases significantly lower at 30-32 months than during acute illness and early convalescence. The significance of the persistence of the IgA anti-HAV and possible reasons for the change in the BR are discussed.     

Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization

Titres of antibodies against hepatitis A virus (HAV) were determined in patients, in donors, and in volunteers after active, passive, and combined immunization. Highest titres were found in recently infected persons: in 109 IgM anti-HAV positive persons, the geometric mean titre (GMT) was 15,400 mlU/ml. The GMT in 265 anti-HAV positive blood donors was 10,700 mlU/ml. The anti-HAV seroprevalence in 19,746 donors increases with age: at the age of 40 years, 50% have antibodies. Titres after active, passive, and combined immunization were studied in three groups: 51 persons received inactivated HAV vaccine at months 0, 1, and 6. The GMT after the booster was 3,400 mlU/ml at month 7. All persons produced more than 100 mlU/ml anti-HAV. Forty-nine persons received both 5 ml immunoglobulin and three vaccinations, yielding a GMT of 1,300 mlU/ml at month 7. One person in this group produced less than 100 mlU/ml anti-HAV. Forty-nine persons received 5 ml immunoglobulin intramuscularly. At day 5 the GMT was 96 mlU/ml. The estimated minimum protective level (10 mlU/ml) was reached in 3 months. Hepatitis A vaccination may supersede the use of immunoglobulin as prophylaxis for travellers to endemic areas. Passive immunization remains necessary for protection during outbreaks. The dosage regimen for passive immunization is based on old studies using preparations with unknown anti-HAV content. Concern regarding the antibody levels in immunoglobulin preparations is justified; the prevalence of HAV antibodies in developed countries continues to fall. Our results indicate that dosage regimens should be reconsidered. Dosage should be deduced logically from the anti-HAV antibody content of the immunoglobulin preparation. © 1993 Wiley-Liss, Inc.     

Transmission of hepatitis A virus among recently captured Panamanian owl monkeys

The presence of antibody to hepatitis A virus (anti-HAV) in 60% of procured owl monkeys (Aotus trivirgatus) held within the United States prompted a study of recently captured A trivirgatus in Panama. Only 2 of 145 newly captured monkeys, but all of 35 A trivirgatus held within a colony for over 100 days, were found to have anti-HAV. Of 41 sero-negative, newly captured monkeys followed prospectively, 25 became infected with hepatitis A virus (HAV) as evidenced by seroconversion or demonstration of virus in the liver at death. Only one monkey that survived over 60 days within the colony was not infected. HAV was identified in the feces of most infected monkeys prior to the development of antibody and was antigenically indistinguishable from human HAV in cross-blocking radioimmunoassays. This colony-centered epizootic provides strong evidence that A trivirgatus is susceptible to HAV and should be investigated further as a potential model of human hepatitis A.     

Multiplex polymerase chain reaction test for the diagnosis of acute viral hepatitis A

Background/Aims

The early diagnosis of acute hepatitis A (AHA) is hindered because serum IgM against hepatitis A virus (HAV) can yield false-negative results during the window period. This study evaluated the diagnostic accuracy of a polymerase chain reaction (PCR) kit for HAV RNA for the diagnosis of AHA.

Methods

Samples were collected from 136 patients with acute severe hepatitis at their admission to Asan Medical Center between June 2010 and July 2010. Samples were analyzed for serum IgM anti-HAV using an immunoassay test and for qualitative HAV RNA using the Magicplex HepaTrio PCR test kit. The diagnostic accuracies of these methods were tested on the basis of clinical and laboratory diagnoses of AHA.

Results

The concordance rate and kappa value between IgM anti-HAV and HAV RNA PCR were 88.2% and 0.707, respectively. For the diagnosis of AHA, the sensitivity and specificity of IgM anti-HAV were 90.7% and 100%, respectively, when an "equivocal" result was regarded as positive; and 79.1% and 100%, respectively, when an "equivocal" result was regarded as negative. The sensitivity and specificity of HAV RNA PCR were 81.4% and 100%, respectively. All four patients with negative IgM anti-HAV and positive HAV RNA PCR results and all four patients with equivocal IgM anti-HAV RNA and positive HAV RNA PCR results were eventually diagnosed with AHA.

Conclusions

The qualitative HAV RNA PCR test has an equivalent diagnostic accuracy for AHA compared to IgM anti-HAV and may be more sensitive during the window period.     

New bacterial absorption method for determination of hepatitis A IgM and IgA antibodies

Antibodies against hepatitis A virus (anti-HAV) can be determined by a commercially available radioimmunoassay (RIA) (HavabTM, Abbott). To discriminate between recent and past hepatitis A infection this RIA was used in combination with absorption with protein A-containing staphylococci. However, nonabsorbable anti-HAV was repeatedly detected in late-convalescent sera using this methods. The nature of these antibodies was studied in serum samples from 12 such patients. In all patients, the late-convalescent sera contained no IgM class anti-HAV as judged by sucrose density gradient centrifugation. The restricted specificity of staphylococcal protein A explains the lack of absorption. Some recently described streptococcal strains capable of binding all IgG subclasses (including IgG3) as well as both IgA subclasses were, therefore, added to the staphylococci. Absorption studies using these strains indicated that the previously nonabsorbable anti-HAV in these 12 patients was mainly of the IgA class. A bacterial mixture including IgA-binding streptococci seems preferable to routine determination of IgM anti-HAV in acute hepatitis A diagnosis. The results also indicate that IgA anti-HAV in serum can persist for more than two years after a hepatitis A infection.     

Evaluation of urine as a clinical specimen for diagnosis of hepatitis a

The present study pertains to the evaluation of urine as a specimen for detection of anti-hepatitis A virus (anti-HAV) antibodies. Immunoglobulin M (IgM), IgG, and IgA capture enzyme-linked immunosorbent assays for hepatitis A were performed on paired serum and urine specimens collected from hepatitis A patients (n = 92), healthy individuals (n = 100), non-A hepatitis patients (n = 70), and patients with nonhepatic diseases (n = 64, including 37 renal disease patients). Hepatitis A patients seropositive for anti-HAV IgM showed 95.65% uropositivity. No false-positive reactions were observed in control groups. The uropositivity of anti-HAV IgM persisted during the convalescent phase of the disease. Anti-HAV IgG uropositivity correlated well with corresponding seropositivity in all groups (P > 0.05 for each). No significant difference between the proportions of serum and urine positivity for anti-HAV IgA was noted (P > 0.05 for each). Using seroreactivity as a "gold standard," the sensitivity and specificity for anti-HAV IgM, anti-HAV IgG, and anti-HAV IgA tests with urine as a specimen were found to be 95.65 and 100%, 97.76 and 76.47%, and 92.23 and 88.18%, respectively. Urine appears to be comparable to serum for diagnosis of recent and past infection with hepatitis A.     

接种3剂甲肝减毒活疫苗8年的免疫学效果

目的 观察接种3剂甲肝减毒活疫苗8年抗体持久性,并与1针法进行了比较.方法 对农村1～7岁HAV易感儿童110人,接种1剂甲型肝炎减毒活疫苗作为B组,选其中一个自然村的42名易感儿童作为A组,按0、2、6个月程序接种3剂疫苗,分别于免疫后1、2、6 7 8、12、24、36和96个月采集血清标本,检测抗-HAV总抗体.结果 B组接种甲肝减毒活疫苗后2～3个月,抗-HAV阳转率和几何平均浓度(GMC)达到高峰,分别为92.2%和126.2 mIU/ml,然后开始随时间下降.与之相比,按照0、2、6个月程序免疫的A组,抗体阳转率在第二针后即达100%,第三针后GMC达高峰,为2739 mIU/ml,A组的近期免疫效果甚至优于灭活疫苗;36～96个月B组的抗-HAV阳转率和GMC分别为75%～71%和80～89 mIU/ml;与之相比,A组36～96个月的抗-HAV阳转率和GMC分别为100%和918.2～480.6 mIU/ml,显著高于B组.结论 接种3剂甲肝减毒活疫苗近期、远期免疫效果均高于一针法,三针法加强免疫取得了良好的免疫学效果,抗体持久性和预防效果有待于进一步观察.